You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Government & Policy Articles
Popular Government & Policy Articles
Highly Recommended Government & Policy Articles
Send a link to this page to your friends and colleagues.
Novartis reports that there will be a three-month delay in approval for its experimental diabetes drug, Galvus, due to the FDA’s request for additional safety data.
On November 13, 2006, Novartis announced that it is submitting further data to the FDA, “meaning that the U.S. regulator’s decision on approving the product will probably come at the end of February, 2007, three months later than expected.”
Galvus is a DPP-IV inhibitor that works by enhancing the body’s own ability to lower blood sugar levels. Merck Co.’s Januvia is also a DPP-IV inhibitor, which was granted FDA approval in October 2006.
0 comments - Feb 1, 2007
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.